A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma: KCSG HN18-07

被引：0
|
作者：
An, Hojung
Keam, Bhumsuk
Shin, Seong Hoon
Kim, Min Kyoung
Kim, Sung-Bae
机构：
[1] Catholic Univ Korea, St Vincents Hosp, Suwon, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[3] Kosin Univ, Gospel Hosp, Busan, South Korea
[4] Yeungnam Univ Univ Hosp, Daegu, South Korea
[5] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6020
引用
收藏
页数：1
相关论文
共 50 条
  • [1] E-TPF (cetuximab, cisplatin, docetaxel, 5-FU) induction chemotherapy in locally advanced squamous cell carcinoma of oral cavity: A phase II study.
    Lu, Hsueh-Ju
    Chang, Mu-Hsin
    Wang, Ling-Wei
    Tai, Shyh-Kuan
    Chen, Ming-Huang
    Chu, Pen-Yuan
    Yang, Muh-Hwa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Wing-Lok Chan
    Cheuk-Wai Choi
    Ian Yu-Hong Wong
    Terence Hon-Ting Tsang
    Adrian Tin-Chung Lam
    Rosa Pui-Ying Tse
    K. K. Chan
    Claudia Wong
    Betty Tze-Ting Law
    Emina Edith Cheung
    Siu-Yin Chan
    Ka-On Lam
    Dora Kwong
    Simon Law
    Annals of Surgical Oncology, 2023, 30 : 861 - 870
  • [3] Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial
    Keil, Felix
    Hartl, Maximilian
    Altorjai, Gabriela
    Berghold, Andrea
    Riedl, Regina
    Pecherstorfer, Martin
    Mayrbaeurl, Beate
    De Vries, Alexander
    Schuster, Judith
    Hackl, Jutta
    Fuereder, Thorsten
    Melchardt, Thomas
    Burian, Martin
    Greil, Richard
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 201 - 210
  • [4] MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Even, C.
    Texier, M.
    Le Tourneau, C.
    Marabelle, A.
    Chaput, N.
    Adam, J.
    Paci, A.
    Broutin, S.
    Ferte, C.
    Breuskin, I.
    Cupissol, D.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Even, C.
    Texier, M.
    Le Tourneau, C.
    Bahleda, R.
    Borcoman, E.
    Vinches, M.
    Toussaint, P.
    Marabelle, A.
    Breuskin, I.
    Cupissol, D.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S682 - S683
  • [6] Cetuximab plus chemoradiation with cisplatin and 5-fluorouracil (5-FU) in locally advanced unresectable esophageal squamous cell carcinoma.
    Sunpaweravong, P.
    Sunpaweravong, S.
    Sangthawan, D.
    Pinaikul, S.
    Attasaranya, S.
    Dechaphunkul, A.
    Mitarnun, W.
    Fungthammasarn, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] The Efficacy and safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin, 5-FU therapy for resectable locally advanced esophageal squamous cell carcinoma
    Ogura, N.
    Yamamoto, S.
    Hirose, T.
    Shiraishi, K.
    Imazeki, H.
    Itoyama, M.
    Yokoyama, K.
    Honma, Y.
    Kurita, D.
    Ishiyama, K.
    Oguma, J.
    Daiko, H.
    Seto, Y.
    Kato, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1479 - S1479
  • [8] TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
    Hideaki Bando
    Daisuke Kotani
    Takahiro Tsushima
    Hiroki Hara
    Shigenori Kadowaki
    Ken Kato
    Keisho Chin
    Kensei Yamaguchi
    Shun-ichiro Kageyama
    Hidehiro Hojo
    Masaki Nakamura
    Hidenobu Tachibana
    Masashi Wakabayashi
    Miki Fukutani
    Yosuke Togashi
    Nozomu Fuse
    Hiroyoshi Nishikawa
    Takashi Kojima
    BMC Cancer, 20
  • [9] TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
    Bando, Hideaki
    Kotani, Daisuke
    Tsushima, Takahiro
    Hara, Hiroki
    Kadowaki, Shigenori
    Kato, Ken
    Chin, Keisho
    Yamaguchi, Kensei
    Kageyama, Shun-ichiro
    Hojo, Hidehiro
    Nakamura, Masaki
    Tachibana, Hidenobu
    Wakabayashi, Masashi
    Fukutani, Miki
    Togashi, Yosuke
    Fuse, Nozomu
    Nishikawa, Hiroyoshi
    Kojima, Takashi
    BMC CANCER, 2020, 20 (01)
  • [10] ASO Visual Abstract: Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Chan, Wing-Lok
    Choi, Cheuk-Wai
    Wong, Ian Yu-Hong
    Tsang, Terence Hon-Ting
    Lam, Adrian Tin-Chung
    Tse, Rosa Pui-Ying
    Chan, K. K.
    Wong, Claudia
    Law, Betty T. T.
    Cheung, Emina Edith
    Chan, Siu-Yin
    Lam, Ka-On
    Kwong, Dora
    Law, Simon
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (02) : 873 - 873
12345